Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Redmile Group

Investor type Hedge Fund


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 152
Average round size
The average size of a deal this fund participated in
Portfolio companies 110
Rounds per year 10.13
Lead investments 27
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 64
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

In 2007 was created Redmile Group, which is appeared as VC. The leading representative office of defined VC is situated in the San Francisco. The venture was found in North America in United States.

Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Foundation Medicine, Afferent Pharmaceuticals Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Redmile Group, startups are often financed by MPM Capital, Third Rock Ventures, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Samsara BioCapital, Rock Springs Capital. In the next rounds fund is usually obtained by Deerfield, Wild Basin Investments, Three Leaf Ventures.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in 7-12 investment rounds annually. This Redmile Group works on 19 percentage points more the average amount of lead investments comparing to the other organizations. When the investment is from Redmile Group the average startup value is 100-500 millions dollars. The high activity for fund was in 2019. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2019.

Besides them, we counted 4 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Redmile Group:
Typical Co-investors
Redmile Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Redmile Group:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AIMCo Colorado, Denver, United States
ArpexCapital Brazil, São Paulo, Sao Paulo
Benson Oak Ventures Herzliya, Israel, Tel Aviv China, Fuzhou, Jiangxi
FINANCIERE FONDS PRIVES France, Ile-de-France, Paris
Guangdong Xiaozhong Touzi China, Guangdong, Zhuhai
Harvest Partners New York, New York, United States
Hongshi Capital Management Beijing, Beijing, China
Indigo Partners Arizona, Phoenix, United States
Lumis Partners Connecticut, Stamford, United States
MkII Ventures California, San Francisco, United States
Natixis France, Ile-de-France, Paris
Nine Four Ventures Chicago, Illinois, United States
OCT China, Fujian, Xiamen
Sumeru Equity Partners California, Foster City, United States
Telluride Venture Fund -
TPP Capital Advisors Japan, Tokyo
VOYAGE GROUP Chiyoda, Japan
Zhangjiagang Dagangcheng China, Jiangsu, Zhangjiagang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ventyx Biosciences

$176M19 Sep 2022 Encinitas, California, United States

Kymera Therapeutics

Health Care
$150M19 Aug 2022 Cambridge, Massachusetts, United States


Clinical Trials
$126M27 Jul 2022 Houston, Texas, United States

Annexon Biosciences

Health Care
Health Diagnostics
Life Science
$130M08 Jul 2022 South San Francisco, California, United States

Scholar Rock

$205M17 Jun 2022 Cambridge, Massachusetts, United States

Rapt Therapeutics

$50M25 May 2022 South San Francisco, California, United States


Health Care
$100M30 Mar 2022 San Francisco, California, United States

Saluda Medical

Health Care
Medical Device
$125M02 Mar 2022 Sydney, New South Wales, Australia

Star Therapeutics

$100M16 Feb 2022 South San Francisco, California, United States
Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Prime Medicine Raises $315M in Funding

– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology.
– The company raised $115M in Series A funding and $200M in Series B funding.
– The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners.
– The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara BioCapital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Redmile Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: